Literature DB >> 25720799

High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity.

Man Chen1, Yao Liu2, Patrick Varley3, Ying Chang4, Xing-Xing He4, Hai Huang3, Daolin Tang3, Michael T Lotze3, Jusheng Lin5, Allan Tsung6.   

Abstract

Liver inflammation plays a critical role in hepatocellular carcinoma (HCC) etiology. Damage-associated molecular patterns (DAMP), such as high-mobility group box 1 (HMGB1), and dysregulated miRNAs involved in inflammatory disease states, such as miR-21, may participate in the link between inflammation and cancer. We sought to determine the role of HMGB1 signaling in HCC tumor progression. We first document the concordant expression increase of HMGB1 and miR-21 in HCC cell lines and primary HCC tumor samples and subsequently show that HMGB1 stimulation results in overexpression of miR-21. These changes were found to be dependent on the IL6/STAT3 signaling axis. Invasion and migration of HCC cells in vitro were inhibited by both STAT3 and miR-21 antagonists, suggesting a role for this pathway in HCC tumor progression. We verified that HMGB1-induced expression of miR-21 in HCC provides a posttranscriptional repression of the matrix metalloproteinase (MMP) inhibitors RECK and TIMP3, which are known to impact HCC progression and metastases. Finally, we found that inhibition of miR-21 in murine HMGB1-overexpressing HCC xenografts led to reduced tumor MMP activity through released repression of the miR-21 targets RECK and TIMP3, which ultimately impeded tumor progression. The prototypical DAMP, HMGB1, is released during liver inflammation and provides a favorable environment for HCC growth. HMGB1 signaling increases miR-21 expression to mediate the enhanced activity of MMPs through RECK and TIMP3. These findings provide a novel mechanism for HMGB1-mediated HCC progression through the IL6/Stat3-miR-21 axis. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25720799      PMCID: PMC4401643          DOI: 10.1158/0008-5472.CAN-14-2147

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  TLR4 knockout protects mice from radiation-induced thymic lymphoma by downregulation of IL6 and miR-21.

Authors:  C Liu; F Gao; B Li; R E J Mitchel; X Liu; J Lin; L Zhao; J Cai
Journal:  Leukemia       Date:  2011-05-27       Impact factor: 11.528

3.  MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression.

Authors:  Bao Song; Chuanxi Wang; Jie Liu; Xingwu Wang; Liyan Lv; Ling Wei; Li Xie; Yan Zheng; Xianrang Song
Journal:  J Exp Clin Cancer Res       Date:  2010-03-27

4.  MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma.

Authors:  Changzheng Liu; Jia Yu; Shuangni Yu; Robert M Lavker; Lei Cai; Wei Liu; Kegong Yang; Xiaodong He; Songsen Chen
Journal:  J Hepatol       Date:  2010-04-04       Impact factor: 25.083

5.  Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation.

Authors:  Christos Polytarchou; Dimitrios Iliopoulos; Maria Hatziapostolou; Filippos Kottakis; Ioanna Maroulakou; Kevin Struhl; Philip N Tsichlis
Journal:  Cancer Res       Date:  2011-05-09       Impact factor: 12.701

6.  High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases.

Authors:  Wei Yan; Ying Chang; Xiaoyan Liang; Jon S Cardinal; Hai Huang; Stephen H Thorne; Satdarshan P S Monga; David A Geller; Michael T Lotze; Allan Tsung
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

7.  RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing--cysteine-rich protein with Kazal motifs.

Authors:  K Furumoto; S Arii; A Mori; H Furuyama; M J Gorrin Rivas; T Nakao; N Isobe; T Murata; C Takahashi; M Noda; M Imamura
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

8.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

Review 9.  Role of microRNA-mediated MMP regulation in the treatment and diagnosis of malignant tumors.

Authors:  Liqin Li; Heng Li
Journal:  Cancer Biol Ther       Date:  2013-08-05       Impact factor: 4.742

Review 10.  MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer.

Authors:  Esmerina Tili; Jean-Jacques Michaille; Carlo M Croce
Journal:  Immunol Rev       Date:  2013-05       Impact factor: 12.988

View more
  42 in total

1.  Circular RNA 101368/miR-200a axis modulates the migration of hepatocellular carcinoma through HMGB1/RAGE signaling.

Authors:  Shaling Li; Huimin Gu; Yan Huang; Qian Peng; Rongrong Zhou; Panpan Yi; Ruochan Chen; Zebing Huang; Xingwang Hu; Yun Huang; Daolin Tang
Journal:  Cell Cycle       Date:  2018-10-22       Impact factor: 4.534

2.  MicroRNA-34a directly targets high-mobility group box 1 and inhibits the cancer cell proliferation, migration and invasion in cutaneous squamous cell carcinoma.

Authors:  Shanshan Li; Chengqun Luo; Jun Zhou; Yong Zhang
Journal:  Exp Ther Med       Date:  2017-10-02       Impact factor: 2.447

3.  Expression of aldehyde dehydrogenase family 1 member A1 and high mobility group box 1 in oropharyngeal squamous cell carcinoma in association with survival time.

Authors:  Xu Qian; Annekatrin Coordes; Andreas M Kaufmann; Andreas E Albers
Journal:  Oncol Lett       Date:  2016-09-07       Impact factor: 2.967

4.  The protein histidine phosphatase LHPP is a tumour suppressor.

Authors:  Sravanth K Hindupur; Marco Colombi; Stephen R Fuhs; Matthias S Matter; Yakir Guri; Kevin Adam; Marion Cornu; Salvatore Piscuoglio; Charlotte K Y Ng; Charles Betz; Dritan Liko; Luca Quagliata; Suzette Moes; Paul Jenoe; Luigi M Terracciano; Markus H Heim; Tony Hunter; Michael N Hall
Journal:  Nature       Date:  2018-03-21       Impact factor: 49.962

Review 5.  TIMPs: versatile extracellular regulators in cancer.

Authors:  Hartland W Jackson; Virginie Defamie; Paul Waterhouse; Rama Khokha
Journal:  Nat Rev Cancer       Date:  2016-12-09       Impact factor: 60.716

Review 6.  Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression.

Authors:  Efthalia Angelopoulou; Christina Piperi; Christos Adamopoulos; Athanasios G Papavassiliou
Journal:  J Mol Med (Berl)       Date:  2016-06-04       Impact factor: 4.599

7.  Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression.

Authors:  Anna Fishbein; Weicang Wang; Haixia Yang; Jun Yang; Victoria M Hallisey; Jianjun Deng; Sanne M L Verheul; Sung Hee Hwang; Allison Gartung; Yuxin Wang; Diane R Bielenberg; Sui Huang; Mark W Kieran; Bruce D Hammock; Dipak Panigrahy
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-14       Impact factor: 11.205

Review 8.  Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment.

Authors:  Ramin Lotfi; Christof Kaltenmeier; Michael T Lotze; Christoph Bergmann
Journal:  Transfus Med Hemother       Date:  2016-03-08       Impact factor: 3.747

Review 9.  Danger signals in liver injury and restoration of homeostasis.

Authors:  Hui Han; Romain Desert; Sukanta Das; Zhuolun Song; Dipti Athavale; Xiaodong Ge; Natalia Nieto
Journal:  J Hepatol       Date:  2020-05-01       Impact factor: 25.083

10.  Targeting HMGB1/TLR4 axis and miR-21 by rosuvastatin: role in alleviating cholestatic liver injury in a rat model of bile duct ligation.

Authors:  Enas S Nabih; Omnyah A El-Kharashi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-09-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.